Aclaris Therapeutics, Inc. (0H8T.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 366.47M |
| Enterprise Value | 350.19M |
| P/E Ratio | -6.9 |
| PEG Ratio | -0.15 |
| Price/Sales Ratio | 99.12 |
| Price/Book Ratio | 3.58 |
| Enterprise/Revenue | 95.93 |
| Enterprise/EBITDA | -7.75 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | September 30, 2026 |
| Profit Margin | -12.44 |
| Operating Margin | -14.14 |
| Return On Assets | -0.37 |
| Return On Equity | -0.59 |
| Revenue | 7.83M |
| Revenue/Share | 0.04 |
| Gross Profit | 542,000 |
| EBITDA | -73.42M |
| Net Income | -64.92M |
| Diluted EPS | -0.53 |
| Total Cash | 114.29M |
| Total Cash/Share | 0.76 |
| Total Debt | 1.71M |
| Total Debt/Equity | 0 |
| Current Ratio | 5.09 |
| Book Value Per Share | 1.12 |
| 52-Week Change | 72.5 |
| 52-Week High | 6.58 |
| 52-Week Low | 2.25 |
| Moving Average 50 Days | 4.5 |
| Moving Average 200 Days | 4.52 |
| Average Volume | 3,801 |
| Shares Outstanding | 158.61M |
| % Held by Institutions | N/A |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |